AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)
281.33 USD
+7.230 2.638%Sponsored Reports
Loading...
| Previous Close (in USD) | 274.1 |
|---|---|
| Change | +7.230 2.638% |
| 52 W H/L (in USD) | 299.980/119.760 |
| EBITDA (in USD) | -453.626M |
| PE Ratio | -- |
| Volume | 134306 |
| Diluted Eps TTM | -23.14 |
| Total Assets (in USD) | 640.547M |
|---|---|
| Total Liabilities (in USD) | 235.214M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 99.915M |
| Market Cap (in USD) | 4,828.973 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Four Tower Bridge, West Conshohocken, PA, United States, 19428
267 824 2827
Employees: 376
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Paul A. Friedman M.D. | Chairman & CEO | 1943 |
| 2. | Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, Pres of R&D and Director | 1952 |
| 3. | Mr. Alex G. Howarth | Sr. VP & CFO | 1969 |
| 4. | Mr. Brian J. Lynch J.D. | Sr. VP & Gen. Counsel | 1962 |
| 5. | Mr. Remy Sukhija | Sr. VP & Chief Commercial Officer | 1972 |
| 6. | Dr. Kianoush Motesharei Ph.d. | Sr. VP of Bus. & Corp. Devel. | 1970 |
| 7. | Mr. Edward Chiang | Sr. VP of Clinical & Technical Operations | NA |
| 8. | Mr. Thomas W. Hare | Sr. VP of Clinical Management | NA |
| 9. | Dr. Robert E. Waltermire Ph.D. | Chief Pharmaceutical Devel. Officer | 1964 |
| 10. | Dr. Stephen Dodge M.B.A., Pharm.D. | Sr. VP of Global Medical Affairs | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -295.35M | -241.846M | -202.244M | -83.948M | -32.811M |
| Minority Interest | - | - | - | - | - |
| Net Income | -299.314M | -241.078M | -197.444M | -72.812M | -32.811M |
| Selling General Administrative | 48.13M | 37.318M | 21.864M | 22.648M | 15.293M |
| Gross Profit | - | 0.273M | 0.022M | - | 0.2M |
| Reconciled Depreciation | 0.467M | 0.405M | 0.471M | 0.112M | 0.096M |
| Ebit | -293.571M | -242.887M | -207.144M | -95.084M | -40.778M |
| Ebitda | -291.386M | -242.482M | -206.673M | -94.972M | -40.682M |
| Depreciation And Amortization | 2.185M | 0.405M | 0.471M | 0.112M | 0.096M |
| Operating Income | -293.571M | -242.482M | -206.673M | -94.972M | -40.682M |
| Other Operating Expenses | 293.571M | 242.482M | 206.673M | 94.972M | 40.682M |
| Interest Expense | 3.964M | 1.041M | 4.329M | 11.024M | 7.671M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 2.185M | 0.363M | 4.329M | 11.024M | 7.671M |
| Net Interest Income | -1.779M | 0.363M | 4.329M | 11.024M | 7.671M |
| Income Tax Expense | 3.964M | -0.768M | -4.8M | -11.136M | 7.871M |
| Total Revenue | 0M | 0.037M | 0.022M | 0M | 0.2M |
| Total Operating Expenses | 293.571M | 242.482M | 206.673M | 94.972M | 40.682M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | -1.779M | 0.636M | 4.429M | 11.024M | 0.2M |
| Net Income From Continuing Ops | -295.35M | -242.119M | -202.344M | -83.948M | -33.011M |
| Net Income Applicable To Common Shares | -295.35M | -241.846M | -202.244M | -83.948M | -32.811M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 640.547M | 362.572M | 273.332M | 286.995M | 442.056M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.15M | 2.595M | 1.338M | 1.014M | 1.152M |
| Total Liab | 235.214M | 165.183M | 77.225M | 47.025M | 25.491M |
| Total Stockholder Equity | 405.333M | 197.389M | 196.107M | 239.97M | 416.565M |
| Other Current Liab | 89.98M | 91.461M | 55.048M | 45.222M | 23.637M |
| Common Stock | 0.002M | 0.002M | 0.002M | 0.002M | 0.002M |
| Capital Stock | 0.002M | 0.002M | 0.002M | 0.002M | 0.002M |
| Retained Earnings | -1336.29M | -962.66M | -667.31M | -425.464M | -223.22M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | - | - | - | - |
| Cash | 99.915M | 331.549M | 36.269M | 54.004M | 46.697M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 118.548M | 115.894M | 76.838M | 46.557M | 25.13M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | 17.278M | -281.658M | -35.472M | -53.218M | -46.021M |
| Short Term Debt | 0.527M | 0.602M | 0.41M | 0.318M | 0.315M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 117.193M | 49.891M | 0.797M | 0.786M | 0.676M |
| Other Stockholder Equity | 1741.153M | 1160.079M | 863.495M | 665.385M | 639.567M |
| Property Plant Equipment | - | 0.601M | 1.648M | 1.047M | 1.184M |
| Total Current Assets | 637.281M | 361.369M | 271.684M | 285.163M | 440.197M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 534.216M | 27.225M | 234.077M | 230.145M | 392.348M |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | 115.48M | 49.289M | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 28.041M | 23.831M | 21.38M | 1.017M | 1.178M |
| Accumulated Other Comprehensive Income | 0.468M | -0.032M | -0.08M | 0.047M | 0.216M |
| Non Currrent Assets Other | - | 1.203M | 0.797M | 1.832M | 1.859M |
| Non Current Assets Total | 3.266M | 1.203M | 1.648M | 1.832M | 1.859M |
| Capital Lease Obligations | 1.713M | 0.602M | 0.797M | 0.786M | 0.676M |
| Long Term Debt Total | - | 49.289M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -502.52M | 206.686M | -4.846M | 160.114M | 30.879M |
| Total Cashflows From Investing Activities | - | 206.686M | -5.055M | 159.78M | 30.707M |
| Total Cash From Financing Activities | 595.116M | 313.451M | 171.237M | 5.088M | 0.235M |
| Net Income | -373.63M | -295.35M | -241.846M | -202.244M | -83.948M |
| Change In Cash | -231.634M | 295.28M | -17.735M | 7.307M | -10.682M |
| Begin Period Cash Flow | 331.549M | 36.269M | 54.004M | 46.697M | 57.379M |
| End Period Cash Flow | 99.915M | 331.549M | 36.269M | 54.004M | 46.697M |
| Total Cash From Operating Activities | -324.23M | -224.857M | -183.917M | -157.561M | -41.624M |
| Depreciation | 0.527M | 0.467M | 0.405M | 0.471M | 0.112M |
| Other Cashflows From Investing Activities | - | - | - | - | 30.879M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - | 0.235M |
| Other Cashflows From Financing Activities | -0.363M | 107.183M | 1.03M | 0.667M | 0M |
| Capital Expenditures | 1.479M | 0.217M | 0.209M | 0.334M | 0.172M |
| Change In Working Capital | -3.276M | 37.604M | 30.651M | 23.482M | 19.453M |
| Other Non Cash Items | 6.624M | 0.797M | 7.32M | 21.833M | 24.292M |
| Free Cash Flow | -325.709M | -225.074M | -184.126M | -157.895M | -41.796M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Janus Concentrated Growth CF | 1 year ago | 637684 |
| 2. | Janus Henderson Forty S | 1 year ago | 637684 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 535753 |
| 4. | Vanguard Small Cap Index | 1 year ago | 427242 |
| 5. | iShares Russell 2000 ETF | 1 year ago | 345296 |
| 6. | Janus Henderson Contrarian D | 1 year ago | 319654 |
| 7. | Janus Henderson US Opportunistic Alpha | 1 year ago | 319654 |
| 8. | T. Rowe Price Health Sciences | 1 year ago | 298624 |
| 9. | Janus Henderson Global Life Sciences | 1 year ago | 294654 |
| 10. | Janus Henderson Global Life Sciences D | 1 year ago | 294654 |
| 11. | Vanguard Small Cap Value Index Inv | 1 year ago | 287091 |
| 12. | SPDR® S&P Biotech ETF | 1 year ago | 278925 |
| 13. | Artisan International Small-Mid Investor | 1 year ago | 251283 |
| 14. | Artisan Non-U.S. Small-Mid Growth Comp | 1 year ago | 251283 |
| 15. | Janus Henderson Triton D | 1 year ago | 249835 |
| 16. | Janus Henderson US SMID Cap Growth | 1 year ago | 249835 |
| 17. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 233184 |
| 18. | Janus Selection Global Life Science AUSD | 1 year ago | 225038 |
| 19. | Janus Henderson Glb Life Scn I2 USD | 1 year ago | 225038 |
| 20. | US Small-Cap Growth II Equity Comp | 1 year ago | 175143 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | HHG PLC | 1 year ago | 2601282 |
| 2. | Baker Bros Advisors LP | 1 year ago | 1969798 |
| 3. | venBio Select Advisor LLC | 1 year ago | 1944444 |
| 4. | Paulson & Company Inc | 1 year ago | 1775000 |
| 5. | Vanguard Group Inc | 1 year ago | 1668806 |
| 6. | BlackRock Inc | 1 year ago | 1212562 |
| 7. | RTW INVESTMENTS, LLC | 1 year ago | 815191 |
| 8. | T. Rowe Price Associates, Inc. | 1 year ago | 803213 |
| 9. | State Street Corporation | 1 year ago | 700739 |
| 10. | FMR Inc | 1 year ago | 625165 |
| 11. | Perceptive Advisors LLC | 1 year ago | 429953 |
| 12. | Artisan Partners Limited Partnership | 1 year ago | 401709 |
| 13. | Geode Capital Management, LLC | 1 year ago | 336255 |
| 14. | Bain Capital Life Sciences Investors, LLC | 1 year ago | 324619 |
| 15. | JANE STREET GROUP, LLC | 1 year ago | 216818 |
| 16. | AlpInvest Partners N.V. | 1 year ago | 211488 |
| 17. | RA Capital Management, LLC | 1 year ago | 204500 |
| 18. | Rock Springs Capital Management LP | 1 year ago | 198169 |
| 19. | Group One Trading, LP | 1 year ago | 191931 |
| 20. | TCG Crossover Management, LLC | 1 year ago | 179917 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...